Innovent Announces Phase 3 CREDIT-5 Met Main Endpoint Study, SINTBILO® (Tafolecimab Injection) as First-Line Monotherapy Treatment for Hyperlipidemia that Impairs Efficacy - Company Announces Company.
Innovent Announces Phase 3 CREDIT-5 Met Main Endpoint Study, SINTBILO® (Tafolecimab Injection) as First-Line Monotherapy Treatment for Hyperlipidemia that Impairs Efficacy - Company Announces Company.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in